The Joslin Clinical Guidelines are designed to be streamlined and disseminated as widely as possible, explained Robert A. Gabbay, MD, PhD, FACP, senior vice president and chief medical officer of Joslin Diabetes Center.
The Joslin Clinical Guidelines are designed to be streamlined and disseminated as widely as possible, explained Robert A. Gabbay, MD, PhD, FACP, senior vice president and chief medical officer of Joslin Diabetes Center.
Transcript
How do you hope the Joslin Clinical Guidelines will be used to reach a wider audience?
We’re really interested in the potential impact of these guidelines to influence care, and they’ve been designed in a way where they’re really streamlined in terms of the length of them. Originally, as I mentioned, we had the Jocelyn textbook of diabetes. People, nowadays, sadly don’t have the time to read textbooks anymore, so this is really a condensed version of distillation of the evidence to say if you’re a healthcare provider, here’s the best evidence on how to manage your patients with diabetes. But also, if you’re a payer and you’re trying to ensure that the quality exists within your network, what should you be looking for in other healthcare providers to be adhering to the best evidence out there? So, we look to really disseminate this as widely as possibly, ultimately, to impact high quality care.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.
Read More